Our study demonstrated that angiotensin II, the plasma concentration of which increases in patients with cirrhotic portal hypertension from 20 to 200 pg/ml (Grace et al., 2012), downregulates the TMEM16A expression in murine PVSMCs. This evidence concerns the gene AGT and portal hypertension.